## **Computationally Efficient Analysis of Randomized Trials with Non-Monotone Missing Binary Outcomes**

Jaron J. R. Lee<sup>1</sup> (jaron.lee@jhu.edu), Daniel O. Scharfstein<sup>2</sup> (dscharf@jhu.edu) and Ilya Shpitser<sup>1,2</sup> (ilyas@cs.jhu.edu) Department of Computer Science<sup>1</sup>, Department of Biostatistics<sup>2</sup>

## Summary

- Missing not at random (MNAR) models are the most realistic model class for studying non-monotone clinical trial data (Little and Rubin, 2014)
- (1) introduce an MNAR model where the probability of missingness at a visit depends on all unobserved outcomes prior to the visit, and all observed outcomes after the visit
- Problem: This model is intractable for large K without further assumptions
- Idea: Develop computational methods to efficiently estimate this model Restrict to binary data
- Introduce a Markov restriction on dependencies
- Use directed acyclic graph (DAG) theory to derive a tractable recursive identification and estimation strategy

## The Unrestricted Robins Model

For  $i = 1, \ldots, K$  time points,

•  $Y_i^{(1)} \in \{0, 1\}$ 

• 
$$R_i \in \{0, 1\}$$

$$Y_i \equiv \begin{cases} Y_i^{(1)}, & R_i = \\ & - \end{cases}$$

$$i \quad (?, \quad R_i = 0)$$

►  $O_k = (R_k, Y_k^{(1)})$ 

- ▶  $\overline{Z}_k = (Z_1, ..., Z_{k-1})$  for k = 2, ..., K,
- $\underline{z}_k = (z_{k+1}, ..., z_K)$  for k = 1, ..., K 1,
- $\overline{Z}_{k}^{m} = (Z_{\max(1,k-m)}, ..., Z_{k-1})$  for k = 2, ..., K,
- $\underline{z}_{k}^{m} = (z_{k+1}, ..., z_{\min(k+m,K)})$  for k = 1, ..., K 1

### Model Assumptions:

$$orall k \in 1, ..., K$$
  
 $p(Y_k^{(1)} | R_k = 0, \overline{Y^{(1)}} = p(Y_k^{(1)} | R_k = 1, \overline{Y_k^{(1)}} ]$ 



**Theorem 1:**  $p(Y^{(1)}_k)$  in the unrestricted model is identified.

- By induction we can show that  $p(Y^{(1)}_k, O_k)$  is identified.
- For k = 0, this is  $p(\underline{O}_1)$  which is observed.
- Suppose identified for k = s. Then,


$$p(\overline{Y^{(1)}}_{s},\underline{O}_{s}) = \sum_{j=0}^{1} p(\overline{Y^{(1)}}_{s-1}, Y^{(1)}_{s}, R_{s} = j, \underline{O}_{s})$$

- $R_s = 1$  is identified by induction.
- $R_s = 0$  is identified since

identified by model assumption

$$\mathcal{D}(\overline{Y^{(1)}}_{s-1}, Y^{(1)}_{s}, R_{s} = 0, \underline{O}_{s}) = \overbrace{\mathcal{D}(Y^{(1)}_{s} \mid R_{s} = 0, \overline{Y^{(1)}}_{s-1}, R_{s} = 0, \underline{O}_{s})}^{\mathcal{D}(\overline{Y^{(1)}}_{s-1}, R_{s} = 0, \overline{Y^{(1)}}_{s-1}, R_{s} = 0, \underline{O}_{s})}_{\text{identified by induction assumption}}$$

▶ **Issue:** The proof relies on probability distributions over  $O(2^K)$  elements (K) binary variables) - inference for large K intractable!




 $\frac{\overline{\mathbf{1}}_{k},\underline{O}_{k}}{\overline{\mathbf{Y}^{(1)}}_{k},\underline{O}_{k}})$ 

\_1, <u>O</u>s)

## **The Restricted Robins Model**

**Solution:** Use Markov restrictions to avoid estimating high-dimensional distributions - related to efficient calculation of causal effects in (2) ▶ Let *m* denote the Markov restriction. At time *t*,



- **Remark:** Since the unrestricted model is identified, the restricted model must also be identified.
- **Remark:**  $p(R_i | \overline{Y^{(1)}}_k^m, \underline{O}_k^m)$  is a probability distribution over  $O(2^{2m})$  elements over large K is tractable for fixed m.

Theorem 2:

 $R_k \perp Y_k^{(1)} \mid \overline{Y^{(1)}}_k^m, \underline{O}_k^m$ 

## **Estimation of the Restricted Model**

The identification of the unrestricted model offers no insight into the estimation of the restricted model that is linear in K for a fixed m. ▶ We derive a *recursive* estimation strategy.

For fixed m, linear in K.

**Base case:** 

$$p(\overline{Y^{(1)}}_{2}^{m+1}, \underline{O}_{1}^{m+1}) = p(O_{m+2} | Y_{1}^{(1)}, \underline{O}_{1}^{m})p(Y_{1}^{(1)} | \underline{O}_{1}^{m})p(\underline{O}_{1}^{m})$$
  
=  $\underbrace{p(O_{m+2} | R_{1} = 1, Y_{1}^{(1)}, \underline{O}_{1}^{m})p(Y_{1}^{(1)} | R_{1} = 1, \underline{O}_{1}^{m})}_{\text{by Theorem 2}} p(\underline{O}_{1}^{m})$ 

**Inductive case:** Assume that  $p(\overline{Y^{(1)}}_{k+1}^{m+1}, \underline{O}_{k}^{m+1})$  is identified. Then,  $p(\overline{Y^{(1)}}_{k+1}^{m+1}, O_{k}^{m+1})$ 

$$= p(O_{k+m+1} \mid \overline{Y^{(1)}}_{k+1}^{m+1}, \underline{O}_{k}^{m})p(Y_{k}^{(1)} \mid \overline{Y^{(1)}}_{k}^{m}, \underline{O}_{k}^{m})$$
  
by Theorem 2  
$$= p(O_{k+m+1} \mid R_{k} = 1, \overline{Y^{(1)}}_{k+1}^{m+1}, \underline{O}_{k}^{m})p(Y_{k}^{(1)} \mid A_{k}^{m})$$

function of  $p(\overline{Y^{(1)}}_2^{m+1}, \underline{O}_1^{m+1})$ 

We want to show that  $p(\overline{Y^{(1)}}_m^m, \underline{O}_{k-1}^{m+2})$  is a function

$$p(\overline{Y^{(1)}}_{k}^{m}, \underline{O}_{k-1}^{m+1}) = \begin{cases} p(\overline{Y^{(1)}}_{k+1}^{m+1}, \underline{O}_{k}^{m+1}), & 2\\ \sum_{Y_{k-m-1}^{(1)}} p(\overline{Y^{(1)}}_{k}^{m+1}, \underline{O}_{k}^{m+1}), & 2 \end{cases}$$

$$p(\overline{Y^{(1)}}_{m}^{m}, \underline{O}_{k-1}^{m+2}) = \int \underbrace{\int \underbrace{O_{k-1}^{m+2}}_{m} \underbrace{\operatorname{by Theo}}_{m} \underbrace{\operatorname{by Theo}}$$

 $\begin{cases} p(O_{k+m+1} \mid \overline{Y^{(1)}}_{k}^{m}, \underline{O}_{k-1}^{m+1}, \overline{R}_{k}^{m} = 1) p(\overline{Y^{(1)}}_{k}^{m}, \underline{O}_{k-1}^{m+1}), & k \leq K - m - 1 \\ p(\overline{Y^{(1)}}_{k}^{m}, \underline{O}_{k-1}^{m+1}), & k > K - m - 1 \end{cases}$ 



## **Model Assumptions:**

 $\forall k \in 1, \ldots, K$  $p(Y_k^{(1)} \mid R_k = 0, \overline{Y^{(1)}}_k^m, \underline{O}_k^m)$  $= p(Y_k^{(1)} \mid R_k = 1, \overline{Y^{(1)}}_k^m, \underline{O}_k^m)$  $p(Y_k^{(1)} \mid \overline{Y^{(1)}}_k) = p(Y_k^{(1)} \mid \overline{Y^{(1)}}_k^m)$ 

(2)


 $(\underline{O}_k^m) p(\overline{Y^{(1)}}_k^m, \underline{O}_k^m)$  $R_{k} = 1, \overline{Y^{(1)}}_{k}^{m}, \underline{O}_{k}^{m}) p(\overline{Y^{(1)}}_{k}^{m}, \underline{O}_{k}^{m})$ 

ion of 
$$p(\overline{Y^{(1)}}_{k+1}^{m+1}, \underline{O}_k^{m+1})$$
.

 $2 \leq k \leq m+1$  $2^{m+1}_{k-1}), \quad m+1 < k \leq K+1$ 

## **Application: Drug Use Abatement Dataset**

- ► *N* = 500, *K* = 24
- Y: negative drug test (abstinence)
- $T = \sum_{k=1}^{24} \mathbb{E}[Y_k^{(1)}]$








Figure 4: Expected treatment effect for varying *m*, with bootstrapped 95% CI (*N*<sub>bootstrap=500</sub>)

## References

- Data. Statistics in Medicine 16, 1 (1997), 21–37.
- pp. 661–670.

# JOHNS HOPKINS UNIVERSITY

Study: National Institute of Drug Abuse Study No. CTN-0044 - evaluating effectiveness of computer tool in outpatient substance abuse treatment. Patient dropout is non-monotone, 20-25% missing.

**Question:** Evaluate effectiveness of treatment vs. control

**Estimation:** Discrete probability distributions estimated using random forests ▶ Use random forests to model  $p(O_K | \underline{O}_K^m), p(O_{K-1} | \underline{O}_{K-1}^m), \dots, p(O_1)$ Tune random forests to avoid positivity violations

Figure 3: Expected abstinences over trial for varying m, with bootstrapped 95% CI ( $N_{\text{bootstrap}} = 500$ )

[1] ROBINS, J. M. Non-Response Models for the Analysis of Non-Monotone Non-Ignorable Missing

[2] SHPITSER, I., RICHARDSON, T. S., AND ROBINS, J. M. An Efficient Algorithm for Computing Interventional Distributions in Latent Variable Causal Models. In Proceedings of the Twenty-Seventh Conference on Uncertainty in Artificial Intelligence (2011), UAI'11, AUAI Press,